AUTHOR=Sánchez-Moya Teresa , López-Nicolás Rubén , Peso-Echarri Patricia , González-Bermúdez Carlos A. , Frontela-Saseta Carmen
TITLE=Effect of pine bark extract and its phenolic compounds on selected pathogenic and probiotic bacterial strains
JOURNAL=Frontiers in Nutrition
VOLUME=11
YEAR=2024
URL=https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1381125
DOI=10.3389/fnut.2024.1381125
ISSN=2296-861X
ABSTRACT=IntroductionInflammatory bowel disease (IBD) comprises a heterogeneous group of chronic diseases as ulcerative colitis (UC) and Crohn’s disease (CD). IBD is the result of a dysregulation of intestinal homeostasis with a host’s loss of tolerance toward normal enteric microflora. Plant-based extracts as phenolic compounds can play a role by modulating the intestinal inflammation response.
MethodsThe in vitro antimicrobial activity of French maritime pine bark extract (PBE) and its phenolic constituents has been investigated in this study. Furthermore, the ability of PBE and phenolic compounds (caffeic acid, chlorogenic acid, ferulic acid, gallic acid and taxifolin) to modulate the microbiota has been assessed.
ResultsPhenolic compounds and PBE showed a great inhibitory effect on the pathogens growth at the highest concentration assessed (1.25 mg/mL). The growth of E. sakazakii and E. faecalis were affected by the effect of caffeic acid and ferulic acid. Taxifolin showed a very strong activity against Listeria sp. (with a reduction ~98%). Gallic acid revealed antibacterial effect on S. aureus at different concentrations. The inhibitory effect of PBE was highly significant on the growth of E. coli O157:H7. PBE, caffeic acid and chlorogenic acid seem to provide the greatest beneficial effect on the probiotic bacteria. However, the highest concentrations of taxifolin may have impaired the growth of beneficial microbiota.
ConclusionPresent findings could be of interest for considering PBE and/or its phenolic constituents as protectors against gastrointestinal disturbances which lead to ulcerative colitis and Crohn’s disease.